2.30
-0.05 (-2.26%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (GB) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | IDORSIA LTD IDORSIA N ORD SHS | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -1.63 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
| IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
|
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 30.75% |
| 机构持股比例 | 15.64% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合